StreetAlpha.app
Home › Stocks › PEPG

PepGen Inc. (PEPG)

Members
LATEST PRICE

PepGen develops treatments for severe neuromuscular diseases, starting with myotonic dystrophy type 1. PEPG reports earnings on Wed, Nov 11, 2026.

Prices, price targets and earnings estimates for PEPG are shown to AI Starter and AI Pro members. Ratings, flow and news are open to everyone.See plans
AI Auto Pilots
Is PEPG in one of our four AI portfolios? Sign in free to see
See how it works→ Details ↓

Earnings

Earnings calendar →
Next report
Nov 11
2026 · Time not announced
Consensus EPS forecast
Members
EPS and revenue estimates
Year-ago EPS
Members
Same quarter last year
Options-implied move
Members
Move priced in by options
Analyst consensus
1 Buy
1 firm · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
1 Buy
1firm
1 Buy0 Hold0 Sell
Only 1 firm rated PEPG in the past 90 days, not enough for a consensus
Average 12-month target
Price targets for PEPGThe average, highest and lowest analyst targets and the target chart are shown to AI Starter and AI Pro members.See plans
Latest rating changes
HC Wainwright & Co.Reiterated
Sep 9Buy
Craig-HallumInitiated
Jun 16Buy
DateFirmActionRatingPrice target
Sep 9HC Wainwright & Co.ReiteratedBuy
Jun 16Craig-HallumInitiatedBuy
Loading…

Seasonality

How PEPG has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2022.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in PEPG in the last 90 days.

Loading…

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether PEPG is in one of them and how their past PEPG trades turned out.

See how it works→ View all auto pilots→
PEPG in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered PEPG in an article yet. Here's the latest on the wider market.

macronewsFriday, October 30, 2026
Binance and Polymarket Hacks Test Crypto's Plumbing, Not Yet Macro
Binance paused withdrawals after a suspected theft of roughly $6 billion, while Polymarket halted trading for an hour after a vendor breach.
Jean Westart · 3 min read
macronewsMonday, October 26, 2026
S&P 500 Sits 2.5% Below Its Record Ahead of the Fed and Big Tech
The S&P 500 slipped 0.47% to 7,623.68, 2.5% below its record, as the Fed meets October 28 and Alphabet, Microsoft and Amazon report.
Marie Crown · 3 min read
macronewsMonday, October 26, 2026
Hightower's Stephanie Link Tells Investors to Add on Volatility
Hightower's Stephanie Link told CNBC's Squawk Box that investors should use market volatility to add to portfolios as earnings season unfolds.
Adam Landser · 2 min read

About PepGen

PepGen is a biotechnology company based in Boston, Massachusetts, that develops treatments for severe neuromuscular and neurologic diseases. Its lead candidate, PGN-EDODM1, is being developed for myotonic dystrophy type 1, a multi-system muscle disease with no approved therapies. The company's proprietary delivery platform uses peptides designed to carry short strands of genetic material into muscle and other cells, aiming to reach the cell nucleus. Its treatments remain in clinical trials and are intended for patients with these conditions.

Headquarters
Boston, MA
Summary based on the company’s 2026 annual report (10-K) ↗